Supernus Return on Investment vs Deferred Revenue Analysis

SUPN Stock  USD 33.79  0.05  0.15%   
Trend analysis of Supernus Pharmaceuticals balance sheet accounts such as Total Current Liabilities of 154.7 M, Total Stockholder Equity of 967.6 M, Property Plant And Equipment Net of 44.7 M or Retained Earnings of 506.7 M provides information on Supernus Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Supernus Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Supernus Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

About Supernus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Supernus Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Supernus Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Supernus Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Supernus currently owns. An asset can also be divided into two categories, current and non-current.

Supernus Pharmaceuticals Balance Sheet Chart

Supernus Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Supernus Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Supernus Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 28th of March 2024, Non Currrent Assets Other is likely to grow to about 8.9 M, while Common Stock Shares Outstanding is likely to drop about 42.6 M.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Supernus Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Supernus Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from Supernus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Supernus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.At this time, Supernus Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 28th of March 2024, Issuance Of Capital Stock is likely to grow to about 8.4 M, while Selling General Administrative is likely to drop about 85.1 M.
 2021 2022 2023 2024 (projected)
Interest Expense23.4M7.1M2.4M2.3M
Depreciation And Amortization34.0M82.6M84.9M89.1M

Supernus Pharmaceuticals fundamental ratios Correlations

0.640.550.360.610.630.420.40.470.350.460.61-0.140.640.70.930.60.450.580.640.910.630.530.690.450.94
0.640.680.630.810.980.770.70.950.630.640.99-0.380.90.980.620.810.760.930.890.840.940.910.940.880.61
0.550.68-0.010.670.550.280.810.50.690.730.62-0.560.850.640.460.670.730.470.710.660.830.60.820.420.49
0.360.63-0.010.450.740.620.140.74-0.010.050.650.050.380.690.380.50.20.730.390.460.380.440.450.660.34
0.610.810.670.450.770.410.780.780.720.310.78-0.420.820.820.540.940.410.830.730.70.830.650.870.780.54
0.630.980.550.740.770.840.570.970.510.530.99-0.270.820.980.630.770.660.940.830.810.850.90.870.890.61
0.420.770.280.620.410.840.270.820.180.480.80.080.580.750.460.470.570.680.60.610.590.890.610.640.43
0.40.70.810.140.780.570.270.580.730.510.66-0.60.850.620.290.830.650.580.660.540.850.610.810.530.31
0.470.950.50.740.780.970.820.580.520.440.96-0.280.780.940.460.750.60.940.790.690.820.880.830.920.43
0.350.630.69-0.010.720.510.180.730.520.540.62-0.710.660.570.30.570.590.620.780.50.780.570.70.690.33
0.460.640.730.050.310.530.480.510.440.540.6-0.270.750.580.470.360.910.350.680.640.740.640.70.350.51
0.610.990.620.650.780.990.80.660.960.620.6-0.380.860.980.60.770.750.940.890.820.910.920.910.90.59
-0.14-0.38-0.560.05-0.42-0.270.08-0.6-0.28-0.71-0.27-0.38-0.38-0.31-0.12-0.34-0.46-0.4-0.6-0.29-0.52-0.29-0.42-0.45-0.14
0.640.90.850.380.820.820.580.850.780.660.750.86-0.380.870.610.880.790.720.820.830.960.80.980.660.62
0.70.980.640.690.820.980.750.620.940.570.580.98-0.310.870.660.790.680.930.860.850.890.850.920.880.66
0.930.620.460.380.540.630.460.290.460.30.470.6-0.120.610.660.570.440.540.660.930.580.530.660.430.99
0.60.810.670.50.940.770.470.830.750.570.360.77-0.340.880.790.570.460.760.670.730.830.660.890.670.56
0.450.760.730.20.410.660.570.650.60.590.910.75-0.460.790.680.440.460.530.820.690.850.760.780.520.45
0.580.930.470.730.830.940.680.580.940.620.350.94-0.40.720.930.540.760.530.820.730.810.80.810.970.53
0.640.890.710.390.730.830.60.660.790.780.680.89-0.60.820.860.660.670.820.820.850.930.830.890.830.64
0.910.840.660.460.70.810.610.540.690.50.640.82-0.290.830.850.930.730.690.730.850.830.750.870.640.92
0.630.940.830.380.830.850.590.850.820.780.740.91-0.520.960.890.580.830.850.810.930.830.840.980.770.59
0.530.910.60.440.650.90.890.610.880.570.640.92-0.290.80.850.530.660.760.80.830.750.840.820.770.53
0.690.940.820.450.870.870.610.810.830.70.70.91-0.420.980.920.660.890.780.810.890.870.980.820.750.66
0.450.880.420.660.780.890.640.530.920.690.350.9-0.450.660.880.430.670.520.970.830.640.770.770.750.42
0.940.610.490.340.540.610.430.310.430.330.510.59-0.140.620.660.990.560.450.530.640.920.590.530.660.42
Click cells to compare fundamentals

Supernus Pharmaceuticals Account Relationship Matchups

Supernus Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding53.8M53.7M54.4M61.7M55.5M42.6M
Total Assets1.2B1.5B1.7B1.7B1.4B1.5B
Short Long Term Debt Total375.6M390.3M420.6M438.0M41.5M39.5M
Other Current Liab3.2M40.0M65.0M139.8M279.9M293.9M
Total Current Liabilities160.6M245.1M315.4M688.0M290.2M154.7M
Total Stockholder Equity595.4M744.9M815.9M886.2M921.5M967.6M
Property Plant And Equipment Net38.3M37.8M17.0M15.2M42.5M44.7M
Net Debt194.2M101.7M217.1M344.8M(33.5M)(31.9M)
Retained Earnings199.5M326.5M379.9M481.2M482.6M506.7M
Accounts Payable10.1M78.9M117.7M96.3M2.0M1.9M
Cash181.4M288.6M203.4M93.1M75.1M116.1M
Non Current Assets Total687.6M873.7M1.1B968.4M915.9M961.7M
Non Currrent Assets Other615K8.0M(36.1M)(10.0M)8.5M8.9M
Cash And Short Term Investments347.1M422.5M339.7M461.3M254.9M201.2M
Net Receivables87.3M140.9M148.9M165.5M144.2M151.4M
Common Stock Total Equity51K52K53K54K62.1K40.8K
Short Term Investments165.7M133.9M136.2M368.2M179.8M98.1M
Liabilities And Stockholders Equity1.2B1.5B1.7B1.7B1.4B1.5B
Non Current Liabilities Total404.3M514.1M557.9M128.3M197.3M179.2M
Inventory26.6M48.3M86.0M91.5M77.4M81.3M
Other Current Assets11.6M18.7M27.0M15.8M16.7M8.5M
Other Stockholder Equity388.4M409.3M434.3M408.1M439.5M279.8M
Total Liab564.9M759.2M873.3M816.3M487.5M333.9M
Property Plant And Equipment Gross38.3M37.8M33.4M28.2M28.9M30.4M
Total Current Assets472.6M630.4M601.6M734.2M493.1M305.3M
Accumulated Other Comprehensive Income7.4M9.0M1.5M(3.2M)(593K)(563.4K)
Intangible Assets24.8M442.3M784.7M702.5M599.9M629.9M
Common Stock51K52K53K54K55K42.0K
Other Liab28.7M123.8M137.4M92.3M106.2M111.5M
Other Assets32.7M259.7M13.9M10.9M12.5M11.9M
Long Term Debt329.5M345.2M361.8M379.3M436.1M457.9M
Property Plant Equipment17.1M37.8M52.3M44.1M50.7M53.2M
Net Tangible Assets570.6M302.6M(86.4M)66.7M76.7M72.9M
Good Will24.8M77.9M117.5M117.0M134.6M141.3M
Retained Earnings Total Equity199.5M326.5M379.9M481.2M553.4M581.1M
Capital Surpluse388.4M409.3M434.3M408.1M469.3M352.1M

Currently Active Assets on Macroaxis

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Supernus Stock analysis

When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
CEOs Directory
Screen CEOs from public companies around the world
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Stocks Directory
Find actively traded stocks across global markets
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.96)
Earnings Share
0.02
Revenue Per Share
11.14
Quarterly Revenue Growth
(0.02)
Return On Assets
0.0056
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.